Hendershot Investments Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,083 shares of the company’s stock after purchasing an additional 2,250 shares during the period. Johnson & Johnson makes up 2.1% of Hendershot Investments Inc.’s holdings, making the stock its 18th biggest holding. Hendershot Investments Inc.’s holdings in Johnson & Johnson were worth $5,470,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. raised its stake in Johnson & Johnson by 3.5% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 1,123,184 shares of the company’s stock worth $136,289,000 after purchasing an additional 38,285 shares during the period. Narwhal Capital Management raised its stake in Johnson & Johnson by 2.5% during the second quarter. Narwhal Capital Management now owns 40,917 shares of the company’s stock worth $4,965,000 after purchasing an additional 1,010 shares during the period. Eagle Global Advisors LLC raised its stake in Johnson & Johnson by 1.6% during the first quarter. Eagle Global Advisors LLC now owns 77,460 shares of the company’s stock worth $9,927,000 after purchasing an additional 1,221 shares during the period. Wealth Alliance Advisory Group LLC raised its stake in Johnson & Johnson by 9.5% during the second quarter. Wealth Alliance Advisory Group LLC now owns 11,274 shares of the company’s stock worth $1,368,000 after purchasing an additional 981 shares during the period. Finally, Chilton Capital Management LLC raised its stake in Johnson & Johnson by 23.6% during the first quarter. Chilton Capital Management LLC now owns 95,055 shares of the company’s stock worth $12,181,000 after purchasing an additional 18,122 shares during the period. 66.60% of the stock is currently owned by institutional investors.
Shares of JNJ opened at $145.34 on Friday. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.32. The stock has a market cap of $382.50 billion, a price-to-earnings ratio of 19.91, a P/E/G ratio of 2.23 and a beta of 0.58. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. During the same period last year, the business earned $1.90 earnings per share. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. As a group, equities research analysts predict that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.48%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 49.32%.
A number of equities analysts have commented on the stock. Citigroup lifted their target price on shares of Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research note on Monday, October 22nd. Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Raymond James lifted their target price on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $142.54.
In related news, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the transaction, the chief operating officer now owns 59,124 shares in the company, valued at $7,969,915.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joaquin Duato sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $144.36, for a total transaction of $5,774,400.00. Following the completion of the transaction, the insider now owns 112,848 shares of the company’s stock, valued at approximately $16,290,737.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 85,340 shares of company stock valued at $11,992,396. Company insiders own 0.22% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Hendershot Investments Inc. Has $5.47 Million Holdings in Johnson & Johnson (JNJ)” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/11/10/hendershot-investments-inc-has-5-47-million-holdings-in-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.